Home Office Circular 019/2018 is concerned with legislation which takes effect from 1st April and which deals with control of pregabalin and gabapentin under the Misuse of Drugs Act 1971 and scheduling under the Misuse of Drugs Regulations 2001. Gabapentin and pregabalin are anticonvulsant drugs, and have an established role in the management of a number of disabling long-term conditions. However, pregabalin and gabapentin had been increasingly reported as drugs with a potential for misuse. They also present a risk of addiction and a potential for illegal diversion and medicinal misuse. Pregabalin and gabapentin are being classified as Class C drugs.